These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 19088696)

  • 1. MIBG for diagnosis and therapy of medullary thyroid carcinoma: is there still a role?
    Castellani MR; Seregni E; Maccauro M; Chiesa C; Aliberti G; Orunesu E; Bombardieri E
    Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):430-40. PubMed ID: 19088696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term prognosis of medullary thyroid carcinoma.
    Rendl G; Manzl M; Hitzl W; Sungler P; Pirich C
    Clin Endocrinol (Oxf); 2008 Sep; 69(3):497-505. PubMed ID: 18331612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Medullary carcinoma of the thyroid: diagnosis and therapy].
    Giuffrida D; Ferraù F; Bordonaro R; Mattina M; Priolo D; Aiello RA; Cordio S; Motta S; Failla G
    Clin Ter; 2000; 151(1):29-35. PubMed ID: 10822879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Usefulness of serum calcitonin, CEA and AFP assays in the early detection of medullary thyroid carcinoma relapse].
    Łacka K; Michałek K; Majewski P
    Wiad Lek; 2002; 55(7-8):394-403. PubMed ID: 12428567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medullary thyroid carcinoma: including MEN 2A and MEN 2B syndromes.
    Quayle FJ; Moley JF
    J Surg Oncol; 2005 Mar; 89(3):122-9. PubMed ID: 15719378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating calcitonin and carcinoembryonic antigen m-RNA detected by RT-PCR as tumour markers in medullary thyroid carcinoma.
    Bojunga J; Dragan C; Schumm-Draeger PM; Usadel KH; Kusterer K
    Br J Cancer; 2001 Nov; 85(10):1546-50. PubMed ID: 11720443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of [131I]metaiodobenzylguanidine therapy in medullary thyroid carcinoma.
    Hoefnagel CA; Delprat CC; Valdés Olmos RA
    J Nucl Biol Med (1991); 1991; 35(4):334-6. PubMed ID: 1823851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclear medicine procedures in the diagnosis and therapy of medullary thyroid carcinoma.
    Rufini V; Castaldi P; Treglia G; Perotti G; Gross MD; Al-Nahhas A; Rubello D
    Biomed Pharmacother; 2008 Mar; 62(3):139-46. PubMed ID: 17892924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medullary thyroid carcinoma: state of the art.
    Favia G; Iacobone M
    G Chir; 2005; 26(11-12):405-9. PubMed ID: 16472416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pretargeted radioimmunotherapy in rapidly progressing, metastatic, medullary thyroid cancer.
    Kraeber-Bodéré F; Salaun PY; Oudoux A; Goldenberg DM; Chatal JF; Barbet J
    Cancer; 2010 Feb; 116(4 Suppl):1118-25. PubMed ID: 20127952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Follow-up in Medullary Thyroid Carcinoma.
    Raue F; Frank-Raue K
    Recent Results Cancer Res; 2015; 204():207-25. PubMed ID: 26494391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medullary thyroid carcinoma: surgical treatment advances.
    Dionigi G; Bianchi V; Rovera F; Boni L; Piantanida E; Tanda ML; Dionigi R; Bartalena L
    Expert Rev Anticancer Ther; 2007 Jun; 7(6):877-85. PubMed ID: 17555398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 131I-MIBG therapy of neural crest tumours (review).
    Troncone L; Rufini V
    Anticancer Res; 1997; 17(3B):1823-31. PubMed ID: 9179240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medullary thyroid carcinoma.
    Leboulleux S; Baudin E; Travagli JP; Schlumberger M
    Clin Endocrinol (Oxf); 2004 Sep; 61(3):299-310. PubMed ID: 15355445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic and therapeutic aspects in medullary thyroid carcinoma.
    Safioleas M; Stamatakos M; Karampali E; Rompoti N; Mouzopoulos G; Lygidakis N
    Chirurgia (Bucur); 2006; 101(2):121-6. PubMed ID: 16752676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors?
    Behr TM; Gratz S; Markus PM; Dunn RM; Hüfner M; Schauer A; Fischer M; Munz DL; Becker H; Becker W
    Cancer; 1997 Dec; 80(12 Suppl):2436-57. PubMed ID: 9406695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of FNA cytology and immunochemistry in the diagnosis and management of medullary thyroid carcinoma: report of six cases and review of the literature.
    Bhanot P; Yang J; Schnadig VJ; Logroño R
    Diagn Cytopathol; 2007 May; 35(5):285-92. PubMed ID: 17427218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Medullary thyroid carcinoma and some of its particularities].
    Sidibé el H
    Sante; 2007; 17(1):51-5. PubMed ID: 17897902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Localization of metastases from medullary thyroid carcinoma using different methods.
    Cabezas RC; Berna L; Estorch M; Carrio I; Garcia-Ameijeiras A
    Henry Ford Hosp Med J; 1989; 37(3-4):169-72. PubMed ID: 2639132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatostatin receptor expression in vivo and response to somatostatin analog therapy with or without other antineoplastic treatments in advanced medullary thyroid carcinoma.
    Vainas I; Koussis Ch; Pazaitou-Panayiotou K; Drimonitis A; Chrisoulidou A; Iakovou I; Boudina M; Kaprara A; Maladaki A
    J Exp Clin Cancer Res; 2004 Dec; 23(4):549-59. PubMed ID: 15743023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.